Business · 24/10/2022
FDA Extends Comment Period for Nonprescription Drug Product Rule
The Food and Drug Administration (FDA) is extending the comment period for a proposed rule regarding a nonprescription drug product with an additional condition for nonprescription use, following requests for an extension from interested persons.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →